Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many ...

Through this collaboration, oncology practices using VieCure Halo Intelligence will be able to order and receive results for Guardant tests for therapy selection and recurrence monitoring ...

Browse 416 market data Tables and 92 Figures spread through 445 Pages and in-depth TOC on "Precision Diagnostics & Medicine Market by Diagnostic Testing (Genetic, DTC), Diagnostics Indication ...

Guardant Health’s first quarter results were shaped by strong growth in both its oncology and screening businesses, with management crediting product upgrades and increasing test volumes as key ...

In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to ...

PALO ALTO, Calif., Jan. 8, 2024 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Hikma Pharmaceuticals PLC ("Hikma"), a multinational pharmaceutical ...

BofA raised Tempus AI's price forecast to $70 but maintained a Neutral rating due to valuation concerns. Guardant Health, Exact Sciences, and LabCorp received Buy ratings for AI-aligned precision ...

Guardant Health, Inc., a leading precision oncology company, today announced its Shield blood test for colorectal cancer screening has been named a winner of Fast Company’ s 2025 World Changing ...

New integration brings Guardant Health's complete oncology testing portfolio into the VieCure Halo Intelligence platform, streamlining access to precision diagnostics at the point of care DENVER ...